- Source Facts: Hanwha Investment & Securities Research Center (Based on the report published on July 6, 2026)
- Investment Opinion & Target Price: BUY Maintained / Target Price Maintained at KRW 760,000
- Key Momentum: Strategic pivot toward localized premium skincare items and total addressable capacity upgrades generating sharp execution beats against internal regional targets.
๐ 1. [Valuation Metrics and Investment Indicator Analysis]
Independent Investment Indicator Summary (Focusing on 2026F Forecasts)
- Target Price & Valuation Framework: Backed by structural risk mitigation and aggressive operational upside into the second half, the target price was sustained at KRW 760,000. The stock is trading at a forward 12M PER of 9.4x, exhibiting an unjustified discount relative to underlying margin expansion.
- Valuation Multiples Matrix: For the 2026F full-year projection, the modeled PER registers at 10.94x, PBR at 2.75x, and EV/EBITDA at 8.76x.
- Return Parameters & Financial Soundness:
- 2026F Return on Equity (ROE) is projected to reach an excellent 27.86%, showcasing robust asset utilization.
- Net debt-to-equity is managed at a tighter 101.49% for 2026F versus 133.55% in 2025, while interest coverage stays secure at 5.15x.
Annual Financial Performance Forecast Trends
- Revenue: KRW 2,166.1 billion in 2024 $\rightarrow$ KRW 2,398.8 billion in 2025 $\rightarrow$ KRW 2,787.2 billion in 2026F.
- Operating Profit: KRW 175.4 billion in 2024 $\rightarrow$ KRW 195.8 billion in 2025 $\rightarrow$ KRW 244.1 billion in 2026F.
- Net Profit (Controlling Interest): Shifting from KRW 123.1 billion in 2025 to KRW 174.6 billion in 2026F, and estimated to hit KRW 223.1 billion by 2027F.
๐ 2. [Market Opportunity (TAM) and Detailed Earnings Estimates]
Quarterly Volume Acceleration and Regional Guidance Beats
- Q2 Outperformance Outlook: For 2Q26, consolidated revenue is modeled at KRW 744.0 billion (+19.3% YoY) and operating profit is forecast at KRW 69.6 billion (+14.4% YoY), indicating highly defensive underlying volume health.
- Multi-Regional Breakthrough Tracks: The parent-level domestic operations achieved +15% YoY (KRW 483.6 billion), supported by massive expansions in China (+21% YoY, KRW 179.8 billion) and the United States (+50% YoY, KRW 45.0 billion). These metrics consistently clear the companyโs preliminary quarterly baseline guidance (domestic 15%, China 20%, US 30%).
- Subsidiary Turnaround Signposts: Most notably, the chronically unprofitable U.S. segment has gained critical mass, printing a forecasted operating profit of KRW 1.4 billion for 2Q26 under an estimated OPM of 3%. Parallel structural inflections are stabilizing in Indonesia (+30%) and Thailand (+10%).
Category Re-balancing and Capacity Optimization Playbooks
- Hydrogel Mask Supply Crunch Opportunities: The surge in skincare order placements from top-tier cross-border digital brands remains a major tailwind. Addressing severe industry-wide capacity shortages for hydrogel items, Cosmax aggressively expanded its production footprint from 3 lines to 8 lines, transforming large-scale volume readiness into a core vendor onboarding asset.
- Mix Correction and Back-Loaded Margin Ramps: As standard cosmetic line disruptions pass their cyclical troughs and product mixes shift toward premium skincare modules, consolidated operating profit margin for the second half is projected to expand by 2%p YoY, locking in a multi-year operating profit surge.
๐ Editor Comment
Cosmax occupies a structural vantage point, acting as the primary volume aggregation tool for the borderless indie brand explosion and record-setting global demand for Korean beauty solutions. Historical valuation headwindsโpreviously centered around execution friction in the U.S., regional volatility across Southeast Asia, and low-margin product mixesโhave been systematically corrected, morphing into operational drivers for margin expansion. The true driver for the back-loaded leg of the cycle is the company’s aggressive, asset-light scale-up in advanced skin-delivery categories, including hydrogel expansions, synchronized with high-volume pipelines into major Western direct distribution frameworks. For long-term portfolios, temporary macro-driven adjustments present a clear opportunity to secure exposure to an elite global compounding node.
๐ข Disclaimer and Source
Source
This content has been newly structured and written based on financial facts and numerical data from officially disclosed securities analysis reports.
Investment Risk Notice
This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific financial instruments. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact
Compliance & Copyright Inquiries
ksb220805@gmail.com
๐ฅ Bulls vs Bears, drop your analysis in the comments!
